Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles
Colorectal Neoplasms
About this trial
This is an interventional diagnostic trial for Colorectal Neoplasms
Eligibility Criteria
Inclusion Criteria:
- Adult patients who are schedule to undergo colonoscopy for a suspicion of colonic neoplasia at the investigators' institution
- Those who agree to participate in the study
Exclusion Criteria:
- Colonoscopy for reasons other than detecting colonic neoplasia, e.g. evaluation of inflammatory bowel disease
- Contraindications to iodinated contrast including renal insufficiency, hypersensitivity, and hyperthyroidism
- Acute severe colonic obstruction which is likely preclude safe and successful performance of CTC
- Patient who is suspicious for colonic perforation
- Pregnancy
- Phenylketonuria (contraindication to simethicone)
Sites / Locations
- Asan Medical Center
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control
Intervention-Oral Simethicone
Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.